Vanda Pharmaceuticals Says FDA Accepted New Drug Application For Tradipitant For Treatment Of Gastroparesis
Portfolio Pulse from Benzinga Newsdesk
Vanda Pharmaceuticals announced that the FDA has accepted its New Drug Application for Tradipitant, aimed at treating Gastroparesis. The FDA's decision is expected by September 18, 2024. If approved, Tradipitant would be the first novel drug for Gastroparesis approved in over 40 years.
December 04, 2023 | 11:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vanda Pharmaceuticals' Tradipitant has been accepted by the FDA for review as a treatment for Gastroparesis, with a decision expected by September 18, 2024.
The acceptance of Tradipitant's NDA by the FDA is a positive development for Vanda Pharmaceuticals, indicating progress in the drug's approval process. The potential approval of Tradipitant could have a significant impact on the company's product portfolio and revenue, as it would be the first novel treatment for Gastroparesis in decades. This news is likely to be viewed positively by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100